Dr. Harvey Zimbler, MD

Dr. Zimbler practices at Northern Light AR Gould Hospital in Presque Isle, Maine, part of Northern Light Health.

Dr. Zimbler's NPI, 1083686224, was assigned on February 2, 2006. Dr. Zimbler graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1972. Dr. Zimbler holds Massachusetts license 40891.

Dr. Zimbler's primary practice is Northern Light AR Gould Hospital, at PO Box 151, Presque Isle, ME 04769 in Aroostook County. The practice phone is (207) 768-4000. Dr. Zimbler also practices at Northern Light AR Gould Hospital, 140 Academy St, Presque Isle, ME 04769.

Dr. Zimbler's primary practice is Northern Light AR Gould Hospital in Presque Isle, Maine, part of Northern Light Health. Dr. Zimbler is also affiliated with Cary Medical Center. The medical group on file is Pines Health Services. Dmand AI also links Dr. Zimbler to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zimbler practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zimbler's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zimbler is licensed in Massachusetts.

CMS data shows 59 Medicare services from Dr. Zimbler across 2 procedure codes in 2024, all of them office visits, for 52 Medicare patients. Medicare paid $5,024 for them. Every service was in an office.

CMS counts 52 Medicare patients who saw Dr. Zimbler in 2024. The largest group is 65 to 74, with 21 patients. 71% of them have high blood pressure, and 67% have high cholesterol. 46% are also on Medicaid. Their average risk score is 2.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zimbler's median patient age at 73, with 51% women.

In 2024, Dr. Zimbler wrote 23 Medicare Part D claims for 14 patients. 91% of them were for generic drugs. They cover 3 drugs, with $117,578 in total drug cost. In 2022, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. Zimbler for performance year 2024, reported as part of a group. Dr. Zimbler accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Zimbler to 10 clinical trials, 9 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 17 general payments to Dr. Zimbler from 5 drug and device companies from 2016 to 2019. Consulting fees make up the largest share, 65% of the total. Puma Biotechnology, Inc. paid the most, $2,846.

Dr. Zimbler graduated from University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) in 1972.